Cargando…
745. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis
BACKGROUND: Mucormycosis is a life-threatening infection that predominantly occurs in immunocompromised hosts. Liposomal amphotericin B (L-AMB) and isavuconazole (ISAV) are commonly used antifungal drugs to treat mucormycosis. However, the efficacy of combination therapy of L-AMB + ISAV compared to...
Autores principales: | Gebremariam, Teclegiorgis, Gu, Yiyou, Singh, Shakti, Kitt, Therese, Ibrahim, Ashraf S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777982/ http://dx.doi.org/10.1093/ofid/ofaa439.935 |
Ejemplares similares
-
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021) -
The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022) -
LB1580. Efficacy Assessment of MAT2203 Encochleated Oral Formulation of Amphotericin B, in the Neutropenic Mouse Model of Pulmonary Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022) -
119. A Humanized Antibody Targeting the CotH Invasins is Protective Against Murine Mucormycosis
por: Gu, Yiyou, et al.
Publicado: (2021) -
Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)